Verberk et al. (2021) note that high-sensitivity tests are required to accurately detect NfH in blood serum, as the use of traditional immunoassays can lead to unreproducible results (Kuhle et al., 2017). Currently, NfL appears to be a better therapeutic biomarker than NfH and is a promising candidate for measuring cerebral axon injury in MS treatment studies (Kuhle et al., 2013). This evidence concerns the gene NEFL and myeloid sarcoma.